← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Privo Technologies, Llc
Peabody, MA
$19,870,320
Total funding
7
Grants
Funding over time
peak $3.2M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,822,953 · 6
FDA$1,047,367 · 1
By mechanism
R44$16,552,334 · 4
N44$2,049,944 · 1
R01$1,047,367 · 1
R43$220,675 · 1
Investigators at Privo Technologies, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)$2,084,026
R44 · FY2024 · CA
TOPIC TITLE: CANCER TREATMENT TECHNOLOGIES FOR LOW-RESOURCE SETTINGSPROJECT TITLE: PRV311: A STANDALONE, SAFE, EFFECTIVE, AND AFFORDABLE TREATMENT FO$2,049,944
N44 · FY2022 · CA
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)$1,245,681
R44 · FY2025 · CA
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy$1,183,038
R44 · FY2021 · DE
FAST TRACK: IND Enabling Studies for Oral Cancer$1,170,342
R44 · FY2017 · CA
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$1,083,847
R44 · FY2019 · CA
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings$1,012,303
R44 · FY2024 · CA
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$1,000,447
R44 · FY2020 · CA
Customized Nanotechnology Based Treatment of Oral Cancer$999,997
R44 · FY2016 · DE
Customized Nanotechnology Based Treatment of Oral Cancer$999,997
R44 · FY2017 · DE
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$999,072
R44 · FY2018 · CA
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings$987,292
R44 · FY2023 · CA
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy$984,664
R44 · FY2023 · DE
FAST TRACK: IND Enabling Studies for Oral Cancer$960,707
R44 · FY2016 · CA
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy$779,005
R44 · FY2022 · DE
Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017$498,400
R01 · FY2020 · FD
Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017$449,307
R01 · FY2019 · FD
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings$401,107
R44 · FY2022 · CA
FAST TRACK: IND Enabling Studies for Oral Cancer$293,491
R44 · FY2015 · CA
Customized Nanotechnology Based Treatment of Oral Cancer$265,000
R44 · FY2016 · DE